Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa
Condition: Healthy Volunteers (Meningococcal Infection) Interventions: Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine; Biological: Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ActHIB | African Health | Children | Diphtheria | India Health | Men | Meningitis | Meningitis Vaccine | Research | South Africa Health | Tetanus | Tetanus Vaccine | Vaccines